-
WilmerHale Represents ExecOnline in Its $45 Million Series D Funding Round
4.21.2021ExecOnline, the pioneer of online leadership development for enterprises, announced a Series D funding round of $45 million led by OMERS Growth Equity.
-
WilmerHale Advises Volastra Therapeutics in Extended $44M Seed Financing
4.6.2021On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million.
-
Recent Venture Financings as Company Counsel: 2021
3.5.2021In 2020, we served as counsel in more than 200 venture financings raising in excess of $10 billion, including some of the largest and most prominent deals of the year. Since 2010, we have handled approximately 2,700 venture financings with total proceeds in excess of $48 billion.
-
WilmerHale Advises Xilio Therapeutics In $95M Series C Financing
2.25.2021On February 24, 2021, Xilio Therapeutics, a biotechnology company developing potent, tumor-selective immunotherapies for patients with cancer, announced the successful closing of a $95 million Series C financing round.
-
WilmerHale Advises Orna Therapeutics in $80M Series A Financing
2.24.2021On February 24, 2021, Orna Therapeutics, a biotechnology company dedicated to designing and delivering a new class of fully engineered circular RNA therapeutics (oRNAs), announced the completion of its $80 million Series A financing.
-
WilmerHale Represents WizeHire in $7.5M Series A Financing
2.19.2021On February 9, 2021, WizeHire, a user-friendly, effective hiring solution for small businesses, announced the closing of $7.5 million in Series A funding.
-
WilmerHale Advises Esme Learning Solutions in $7.5M Series A Financing
1.27.2021Esme Learning Solutions, a leading digital learning platform, announced the close of a $7.5 million Series A financing round led by Adit Ventures, a venture capital firm with a technology thematic investment focus.
-
WilmerHale Represents Verve Therapeutics in $94M Series B Financing
1.22.2021On January 19, 2021, Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, announced the successful completion of a $94 million Series B financing.
-
WilmerHale Advises Werewolf Therapeutics in $72M Series B Financing
1.8.2021On January 7, 2021, Werewolf Therapeutics, an oncology biotherapeutics company advancing a pipeline of next-generation, transformative cancer treatments, announced the completion of its $72 million Series B financing.
-
WilmerHale Represents The Lifetime Value Co. in $150M Investment
12.17.2020On December 17, 2020, The Lifetime Value Co., a creator of leading online consumer and business information brands that helps people discover, understand and use data, announced a $150 million investment led by Morgan Stanley Expansion Capital with participation from investment funds managed by Morgan Stanley Credit Partners, Morgan Stanley Tactical Value, and ROCA Partners.
-
WilmerHale Represents MineralTree in $50M Series D Funding Round and Acquisition of Regal Software
9.25.2020On September 24, 2020, MineralTree, an Accounts Payable (AP) and payments automation solution provider, announced that it has closed a $50 million Series D investment round with participation from existing investors Great Hill Partners, .406 Ventures and Eight Roads Ventures.
-
2020 IPO, Venture Capital and M&A Reports
6.29.2020WilmerHale’s annual IPO, Venture Capital and M&A Reports offer insights into market conditions and provide comprehensive statistics and analysis that are hard to find elsewhere.
-
2020 M&A Report
6.29.2020The 2020 M&A Report provides a detailed global M&A market review and outlook, as well as insights on key topics.
-
2020 IPO Report
6.29.2020The 2020 IPO Report offers a detailed IPO market review and outlook, plus useful market metrics and articles on topics of interest for pre-IPO companies.
-
2020 Venture Capital Report
6.29.2020The 2020 Venture Capital Report offers an in-depth US venture capital market review and outlook, including industry and regional breakdowns, as well as insights on a number of key topics.
